NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial
Company Announcements

NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial

NeuroBo Pharmaceuticals (NRBO) has issued an update.

NeuroBo Pharmaceuticals, Inc. has successfully completed the enrollment for the first part of its Phase 1 clinical trial for DA-1726, a promising new drug aimed at treating obesity. The trial has included 45 participants across 5 cohorts to test the efficacy of the OXM analog agonist. The company issued a press release to announce this milestone, cautioning that the forward-looking statements are not guarantees of future results, and actual outcomes could vary. The press release is part of a regulatory filing that, while not constituting an official filing for securities law purposes, is necessary for corporate transparency.

See more insights into NRBO stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNeuroBo Pharmaceuticals Completes Phase 2a Trial for MASH Drug
TheFlyNeuroBo Pharmaceuticals completes last patient visit in Phase 2a DA-1241 trial
TipRanks Auto-Generated NewsdeskNeuroBo Pharmaceuticals Unveils Updated Corporate Presentation
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App